Arovella Therapeutics Limited (AU:ALA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Arovella Therapeutics Limited, listed on ASX as ALA, is making significant strides in advancing its iNKT cell therapy platform, with plans to commence a phase 1 clinical trial for ALA-101 targeting CD19-positive blood cancers. The company is financially robust, holding $13.2 million in cash and equivalents, which supports its ongoing research and development initiatives. Arovella has also formed a Clinical Advisory Board with leading experts to guide its progress in the cancer therapy landscape.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.